Beyond the CE Mark: A Call to Action for Minimum CGM Accuracy Standards in Central and Eastern European Nations
Open Access
- 14 September 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 9747-9752
Abstract
No abstract availableFunding Information
- Abbott Diabetes Care
This publication has 19 references indexed in Scilit:
- CGM Accuracy in a Fragmented Regulatory Landscape: A Commentary on Harmonisation and Recent EvidenceDiabetes, Obesity and Metabolism, 2026
- International clinical opinion on transparency, standardisation, and calibration alignment in the performance evaluation of systems for continuous glucose monitoringDiabetes, Obesity and Metabolism, 2026
- Clinical assessment and acceptance criteria for continuous glucose monitoring (CGM) system performance: A proposed guideline by the IFCC Working Group on CGMClinica Chimica Acta, 2025
- Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0Diabetes Research and Clinical Practice, 2025
- Proposed minimum requirements for market approval of continuous glucose monitoring ( CGM ) systems: A viewpoint from the IFCC working group on CGMDiabetes, Obesity and Metabolism, 2025
- The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetesDiabetes Research and Clinical Practice, 2025
- Minimum expectations for market authorization of continuous glucose monitoring devices in Europe—‘ eCGM ’ compliance statusDiabetes, Obesity and Metabolism, 2024
- The Myth of MARD ( M ean A bsolute R elative D ifference): Limitations of MARD in the Clinical Assessment of Continuous Glucose Monitoring DataDiabetes Technology & Therapeutics, 2024
- CGM accuracy: Contrasting CE marking with the governmental controls of the USA ( FDA ) and Australia ( TGA ): A narrative reviewDiabetes, Obesity and Metabolism, 2023
- Accuracy Evaluation of Four Blood Glucose Monitoring Systems in Unaltered Blood Samples in the Low Glycemic Range and Blood Samples in the Concentration Range Defined by ISO 15197Diabetes Technology & Therapeutics, 2015